The NIPT market size is expected to advance at a CAGR of 9.8% during 2021–2030, to reach $9,229.2 million by 2030. This is ascribed to the increasing prevalence of chromosomal abnormalities, especially with the increasing age of the mother, and growing demand for early detection methods.
Specifically, the market is expected to be driven by the increasing prevalence of Down syndrome and the growing adoption of advanced non-invasive tests. The rapid advancements in R&D for genetic disorders by research institutes will also drive the usage of NIPT.
Many biotechnology companies provide customizable non-invasive prenatal tests for the detection of single-gene disorders. Rolling circle amplification is a novel technology that targets cell-free DNA and generates fluorescently labeled DNA molecules via the rolling mechanism; the DNA fragments can be counted digitally.
An incidence of 1 in 850 live births has been detected for Down syndrome using these advanced tests. Other highly prevalent genetic disorders are Edward syndrome and Patau syndrome, although their incidence is lower than Down syndrome. The high risk of genetic disorders with the increasing maternal age has led to a rise in prenatal testing demand and the development of advanced tests for the same. The reasons behind delayed pregnancy are low sperm count, ovulation irregularities, structural problems in the reproductive system, hormone imbalance, obesity, and polycystic ovarian syndrome.
In the APAC region, governments have implemented various schemes to enhance the awareness on novel technologies for NIPT, which is contributing toward the growth in prenatal screening volume.
In developing nations, such as India and China, the demand is increasing significantly for the early diagnosis of chromosomal abnormalities during pregnancy. Furthermore, the market is propelled by the increasing per capita income, rising availability of advanced non-invasive prenatal screening products, and surging incidence of abnormalities in the genes.
Moreover, North America holds the largest share due to the robust healthcare infrastructure, along with the easy access to innovative technologies and skilled healthcare professionals for handling the instruments. Additionally, there are several insurance plans provided by public and private agencies in the U.S. to pregnant women, in order to support them financially.
Europe will observe significant growth in the forecast period as well because of the high count of diagnostic labs with advanced technologies. With NIPT, fetuses at a risk of genetic disorders can be identified at an early stage and treated. The NIPT approach was approved in England in 2021, and the government now also provides strong reimbursement support to pregnant women for these tests.
Additionally, the introduction of novel tests by key players, such as Yourgene Health and Medgenome, are making the tests easily accessible to the masses, thereby driving the industry. Moreover, government organizations in the U.K. have implemented many public health policies for creating awareness about non-invasive testing, which is helping in generating high revenue for companies that provide the associated products.
The most-significant NIPT market players are Sequenom Inc., Ariosa Diagnostics Inc., Natera Inc., Illumina Inc., Eurofins LifeCodexx Inc., MedGenome Labs Ltd., Yourgene Health plc, F. Hoffman-La Roche Ltd., Genesis Genetics, CENTOGENE GmbH, Myriad Women’s Health Inc., Progenity Inc., PerkinElmer Inc., and Agilent Technologies Inc.